Allogene Therapeutics, Inc. (ALLO): IPOs News

Key Facts Surrounding This News Item


  • Allogene Therapeutics, Inc. (ALLO - Get Rating) had returned 0.00% year-to-date leading up to today’s news, versus a 0.00% return from the benchmark S&P 500 during the same period.

More Info About Allogene Therapeutics, Inc. (ALLO)


Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the research, development, and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, a CAR T cell product candidate targeting CD19, which is in clinical trials in patients with R/R B-cell precursor acute lymphoblastic leukemia; ALLO-501, an allogeneic anti-CD19 CAR T cell product candidate for the treatment of patients with R/R non-Hodgkin lymphoma; ALLO-715, an allogeneic CAR T cell product candidate for the treatment of patients with R/R multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepleting agent. It is also developing ALLO-819, an anti-Flt3 product candidate for the treatment of acute myeloid leukemia; CD70 for the treatment of renal cell cancer; and DLL3 for the treatment of small cell lung cancer. The company was founded in 2017 and is based in South San Francisco, California. View our full Allogene Therapeutics, Inc. (ALLO - Get Rating) ticker page with ratings, news, and more.

9 "Must Own" Growth Stocks For 2019

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Top Stories on StockNews.com

NASDAQ: IOVA | Iovance Biotherapeutics, Inc. News, Ratings, and Charts

8 Extreme Value Stocks

POWR Rating of A + 44-99% upside potential = 8 extreme value stocks to explore today.
: APRN | Blue Apron Holdings, Inc. Class A Common Stock News, Ratings, and Charts

What caused Blue Apron Holdings (APRN) stock to tank today?

Shares of Blue Apron sank amid announcement of reverse stock split
: CGC | Canopy Growth Corporation Common Stock News, Ratings, and Charts

Canopy Growth (CGC) reminds shareholders to vote in favor of a potential acquisition

Canopy Growth encourages shareholders to vote before the deadline Monday at 10:00 am
NYSE: SLB | Schlumberger N.V. Common Stock News, Ratings, and Charts

After recent weakness, is oil services company Schlumberger (SLB) a Buy?

Schlumberger's deep pullback could be a good opportunity for value investors
NYSE: DIS | Walt Disney Company (The) Common Stock News, Ratings, and Charts

Disney (DIS) is on track to set a box office record this year, is their stock a Buy?

Disney could earn more than $9 billion at the global box office

Read More Stories


More Allogene Therapeutics, Inc. (ALLO) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All ALLO News
Page generated in 1.2149 seconds.